Glaucoma therapeuticAlternative Names: IOP Lowering - Allergan
Latest Information Update: 25 Mar 2017
At a glance
- Originator Allergan
- Mechanism of Action Prostaglandin agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 05 Apr 2011 Phase-II development is ongoing in USA
- 04 Dec 2008 Phase-II clinical trials in Glaucoma in USA (Ophthalmic)
- 28 Apr 2008 Phase-I clinical trials in Glaucoma in USA (Ophthalmic)